SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

Spectrum Pharmaceutecals, Inc. (SPPI)

SPPI RSS Feed
Add SPPI Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/25/2017 1:58:09 PM - Followers: 75 - Board type: Free - Posts Today: 0

http://www.spectrumpharm.com/

http://finance.yahoo.com/q/ks?s=SPPI+Key+Statistics

Company Presentation

http://www.sppirx.com/704-corporate-presentation.html

Spectrum Development Pipeline/Portfolio

Fusilev® (Levoleucovorin) for injection FDA Approved on April 29, 2011 for Use in Patients with Advanced Metastatic Colorectal Cancer and FDA Approved on March 7, 2008 for High-Dose Methotrexate Rescue Therapy in Osteosarcoma.
Zevalin® (ibritumomab tiuxetan), an FDA-Approved, Proprietary, Biological Drug for Indolent Non-Hodgkin's Lymphoma.
Belinostat a novel HDAC inhibitor in late stage clinical development for Peripheral T-cell Lymphoma, and other Solid Tumors (including Carcinoma of Unknown Primary, etc.)
Apaziquone, one of our lead development candidates, is a synthetic bio-reductive prodrug that is being investigated in the treatment of non-invasive bladder cancer, and began two Phase 3 studies in 2007.Spectrum also has three drugs in the Phase 2 stage of development: Ozarelix, for the treatment of prostate cancer and Ortataxel, for the treatment of taxane-refractory tumors.
The Company has three drugs in the Phase 1 stage of development: SPI-1620, an adjunct to chemotherapy, Elsamitrucin, which will target advanced solid tumors and Lucanthone, a chemotherapy sensitizer in the treatment of recurrent, malignant brain tumors.
Other drugs in development include SPI-014, used in the treatment of hyperphosphotemia in end stage renal disease (ESRD), and SPI-205 for chemotherapy induced neuropathy.

Recent News (Zevalin):

http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=632354
http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=632346

.  

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SPPI
Current Price
Volume:
Bid Ask Day's Range
SureTrader
SPPI News: Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast 04/25/2017 07:00:00 AM
SPPI News: Statement of Changes in Beneficial Ownership (4) 04/19/2017 04:26:03 PM
SPPI News: Proxy Statement (definitive) (def 14a) 04/17/2017 02:06:34 PM
SPPI News: Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer R... 04/04/2017 07:00:00 AM
SPPI News: Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) & BELEODAQ® (belinostat) for injection a... 03/31/2017 07:00:00 AM
PostSubject
#1649   "There're no approved treatments for PTCL in Europe." antihama 04/25/17 01:58:09 PM
#1648   Projected Headline- Spectrum Pharma Beats on Q1 Revenue antihama 04/25/17 08:34:54 AM
#1647   A ‘bon sentiment’ to the announced Q1 CC antihama 04/25/17 08:03:11 AM
#1646   7.5% increase in S/P Thursday coincided with Jefferies antihama 04/24/17 08:51:41 AM
#1645   To laugh or cry after reading about neratinib antihama 04/19/17 07:54:48 PM
#1644   antihama 04/10/17 09:05:57 PM
#1643   Regarding your Q on Evomela’s market share potential antihama 04/10/17 08:26:11 PM
#1642   Mystery solved regarding Wed's 30c decline. It coincided antihama 04/09/17 08:21:24 AM
#1641   Here's an Analyst Research article from postanalyst.com on antihama 04/08/17 08:23:24 AM
#1640   Spectrum Pharma owns ~20% of CASI. Here's a antihama 04/06/17 07:35:26 PM
#1639   Seeing Poziotinib’s sales potential through Tagrisso’s eyes. Tagrisso antihama 04/01/17 09:46:13 AM
#1638   Of course the $64,000 question regarding Poziotinib in antihama 03/30/17 09:05:29 AM
#1637   Ha! There is no truth I work for antihama 03/30/17 08:48:11 AM
#1636   Wow. The P2 Poziotinib in EGFR Exon antihama 03/29/17 12:14:24 PM
#1635   Revising my sales projection for Evomela upwards to antihama 03/24/17 12:42:37 PM
#1634   Sanofi and Regeneron were hit w a CRL antihama 03/22/17 08:51:19 PM
#1633   based on these findings, a PI volasertib/belinostat trial antihama 03/22/17 03:53:59 PM
#1632   And another AACR Belinostat abstract to be presented! antihama 03/22/17 03:45:33 PM
#1631   AACR Belinostat abstract to be presented. More interesting antihama 03/21/17 05:59:57 PM
#1630   Great break down much appreciated. tyfoidhana 03/20/17 02:54:05 AM
#1629   I think the rise in PPS is due antihama 03/17/17 04:21:13 PM
#1628   I see you seem to have a real tyfoidhana 03/16/17 10:30:41 PM
#1627   Slides on Evomela from Ligand's presentation at the antihama 03/15/17 04:26:32 PM
#1626   And this article from Amgen's point of view. antihama 03/14/17 09:59:07 PM
#1625   As a follow-up, today's 10k indicates they still antihama 03/14/17 07:54:43 PM
#1624   The 2016 10k issued today has the same antihama 03/14/17 07:23:50 PM
#1623   $6, 7 or 8? Where is the SP antihama 03/14/17 10:57:09 AM
#1622   The Games People (and Tutes) Play. Before I antihama 03/13/17 08:07:14 PM
#1621   The small business opportunity I was referring to antihama 03/13/17 05:21:54 PM
#1620   ..take advantage of a small business opportunity..? Can stugwins 03/13/17 04:47:46 PM
#1619   the company opportunistically repurchased $10 million face value antihama 03/12/17 02:19:18 PM
#1618   Reading the 10K, I'm more excited about Qapzola. antihama 03/12/17 12:33:05 PM
#1617   Random thoughts from the 4th Q CC antihama 03/10/17 10:31:21 AM
#1616   Happy 1 year Anniversary Evomela! According to Kurt antihama 03/10/17 09:27:31 AM
#1615   Actually, after revisiting the CC, I see the antihama 03/09/17 07:01:58 AM
#1614   the only scenario that makes sense is that stugwins 03/08/17 11:46:58 PM
#1613   During the CC, they mentioned 3 times (once antihama 03/08/17 08:31:30 PM
#1612   Have no idea how he came up with stugwins 03/08/17 07:32:30 PM
#1611   Hold the phone. Market for Evomela is 107M! antihama 03/08/17 06:22:22 PM
#1610   You are too kind. There goes my streak antihama 03/08/17 06:06:23 PM
#1609   Pretty good estimates for a couple but missed stugwins 03/08/17 04:52:31 PM
#1608   This is interesting. Coherus Addresses Trade Secret Action antihama 03/06/17 04:39:06 PM
#1607   I was basing it on the total market antihama 03/02/17 07:49:28 AM
#1606   Something does't add up... The total Melphalan market stugwins 03/01/17 10:26:52 PM
#1605   By hook or by crook, my prediction for antihama 03/01/17 05:06:57 PM
#1604   Thx! What's your take on current products (especially Evomela)? stugwins 03/01/17 12:34:34 PM
#1603   My take on the RBC Healthcare Conference on antihama 02/28/17 04:40:58 PM
#1602   Eureka! New P2 trial - Poziotinib in EGFR antihama 02/28/17 03:14:03 PM
#1601   Sure. Hopefully tomorrow. maybe Wednesday. antihama 02/27/17 09:36:24 PM
#1600   I would greatly appreciate your thoughts on the call stugwins 02/27/17 03:21:06 PM
PostSubject